FDA Authorizes Novavax’s Updated COVID Jab Based on Data From Previous Versions

The FDA authorized the updated Novavax jab based on previous clinical trial data rather than solely new clinical trial data for the latest vaccine formulation.

A sticker reading, "COVID-19/Coronavirus vaccine/Injection only" and a medical syringe in front of a displayed Novavax logo in a photo illustration taken on Oct. 31, 2020. Dado Ruvic/Illustration/Reuters

The Food and Drug Administration (FDA) on Tuesday granted emergency use authorization (EUA) to an updated version of Novavax’s COVID-19 vaccine based on safety data from previous versions.

The Oct. 3 EUA allows people aged 12 and above to receive a dose of the new Novavax vaccine, regardless of their prior vaccination history, according to a news release.